Skip to content
peptide

CJC-1295 (no DAC) / Mod GRF 1-29

moderateResearch Use OnlyInjection

Shorter-acting GH booster that releases growth hormone in natural pulses. Clears faster without DAC, so it's usually paired with another GH peptide for stronger effect.


Key facts
Classification
Modified GRF (1-29), a truncated GHRH analog with substitutions at positions 2, 8, 15, and 27 for enhanced receptor affinity and DPP-IV resistance.
Primary benefits
Muscle Growth (7/10) · Fat Loss (6/10) · Longevity (4/10)
Administration
Injection
Doses studied
100 mcg subq 2-3 times daily, ideally paired with a GH-releasing peptide like Ipamorelin. Cycle for 8-12 weeks.
Evidence strength
Moderate — 15 peer-reviewed studies
Stacks well with
Ipamorelin, GHRP-6, GHRP-2
Legal status
Research Use Only · not prescribable in US · WADA prohibited
Quick stats
Type
Peptide
Administration
Injection
Studies referenced
15
Stacks with
3 peptides
Regulatory
Research Use Only
Scientific overview

Modified GRF (1-29), a truncated GHRH analog with substitutions at positions 2, 8, 15, and 27 for enhanced receptor affinity and DPP-IV resistance. ~30-minute half-life produces acute GH pulses mimicking physiological secretion. Often combined with Ipamorelin for synergistic pituitary stimulation.

Goal coverage · CJC-1295 (no DAC) / Mod GRF 1-29
💪 Muscle Growth7/10
🔥 Fat Loss6/10
Longevity4/10
😴 Sleep4/10
🩹 Injury Healing3/10
FIG.1  Modeled goal coverage from reviewed studies. Score out of 10.
Medical oversight strongly recommendedNot safe during pregnancy· 4 contraindications
From our network:Cornerstone Peptide